In addition, pretreatment with 1–20 μΜ linsitinib inhibited the IGF-1-induced expression of cyclin D1 in OFs from TAO patients (pretreatment with 20 μM linsitinib + treatment with IGF-1 by 0.24 fold vs only IGF-1 treatment by 2.40 fold, Fig 2B). Here, CCND1 is linked to thromboangiitis obliterans.